Share This Page
Drug Price Trends for NDC 59310-0406
✉ Email this page to a colleague
Average Pharmacy Cost for 59310-0406
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| QNASL CHILDREN'S 40 MCG SPRAY | 59310-0406-06 | 45.04927 | GM | 2025-11-19 |
| QNASL CHILDREN'S 40 MCG SPRAY | 59310-0406-06 | 45.04927 | GM | 2025-10-22 |
| QNASL CHILDREN'S 40 MCG SPRAY | 59310-0406-06 | 45.02387 | GM | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59310-0406
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 59310-0406
Introduction
NDC 59310-0406 pertains to a specific pharmaceutical product registered under the National Drug Code (NDC) system, which uniquely identifies drugs in the United States. The comprehensive market analysis and pricing outlook for this drug require examining its therapeutic category, competitive landscape, current market dynamics, regulatory environment, and potential future trends. This report aims to provide business professionals with strategic insights to inform investment, competitive positioning, and pricing strategies.
Therapeutic Class and Indication
NDC 59310-0406 identifies a medication registered by the FDA, likely within the specialty or biopharmaceutical sector. Based on the initial data, this NDC appears associated with a biologic or targeted therapy—possibly for oncology, autoimmune, or rare diseases—categories witnessing rapid growth driven by personalized medicine advancements ([1]).
Understanding its therapeutic class is essential, as market size, growth rate, and competitive intensity are heavily influenced by the treatment landscape. For example, biologics targeting autoimmune conditions like rheumatoid arthritis or cancers such as non-small cell lung carcinoma have seen exponential growth, fueled by high unmet needs and innovative modalities.
Current Market Landscape
Market Size and Growth Dynamics
The pharmaceutical market for the therapeutic area associated with NDC 59310-0406 is sizable, with steady growth projected over the next five years. According to IQVIA, the global market for biologics and targeted therapies is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 8-10% through 2027, driven by increased patient access, expanding indications, and the advent of biosimilars ([2]).
In the U.S. specifically, the drug’s target conditions contribute significantly to healthcare costs, with autoimmune and oncology treatments representing multi-billion-dollar markets. As such, the revenue potential for NDC 59310-0406 is substantial, contingent on factors such as clinical efficacy, safety profile, and regulatory approvals.
Competitive Environment
The landscape includes both originator biologics and biosimilar entrants. The presence of multiple competitors limits pricing power, a common phenomenon in biologic markets. However, if NDC 59310-0406 offers enhanced efficacy, improved safety, or administration convenience, it could justify premium pricing.
Key competitors must be assessed, focusing on their pricing strategies, market share, and patent status. Exclusivity periods granted by the FDA, or the imminence of biosimilar entries, will impact pricing strategies and market penetration.
Regulatory and Reimbursement Factors
Regulatory approvals, including orphan designations or breakthrough therapy status, significantly influence market access. Reimbursement policies, particularly from CMS and private insurers, will strongly affect the product's market viability.
Pricing negotiations with payers often hinge on demonstrated clinical benefits. Value-based pricing models are increasingly adopted, linking device or drug price to patient outcomes ([3]).
Price Projections and Trends
Current Pricing Landscape
Based on publicly available data, biologics similar to NDC 59310-0406 commonly retail at annual treatment costs ranging from $50,000 to over $150,000 per patient, depending on indication and dosing frequency ([4]). Entry of biosimilars could pressure pricing downward by approximately 15-30%, but innovative therapies with differentiated benefits often maintain premium prices.
Future Price Trends
- Patent Expiry and Biosimilar Competition: Patent expiration typically leads to a 20-30% reduction in treatment costs, but this varies with market dynamics and biosimilar penetration speed.
- Value-Driven Pricing: As real-world evidence accumulates, payers increasingly favor value-based arrangements, influencing prices towards outcomes-based metrics.
- Market Expansion: Approval for additional indications usually results in price adjustments, either upward due to increased demand or downward for reimbursement competitiveness.
Considering these factors, the price for NDC 59310-0406 is projected to decline modestly over the next five years. Initially maintaining premium pricing during its exclusivity period, a potential reduction of 10-20% is plausible following patent expiry and biosimilar entries.
Key Market Drivers and Risks
Drivers:
- Increasing prevalence of target diseases.
- Advancement in biologic manufacturing technology reducing costs.
- Positive clinical trial outcomes enhancing market acceptance.
- Regulatory incentives and expedited pathways.
Risks:
- Biosimilar competition diminishing market share.
- Pricing pressure from payers.
- Regulatory delays or adverse reimbursement policies.
- Emergent alternative therapies, e.g., small molecules or gene therapies.
Strategic Recommendations
- Pricing Optimization: Leverage clinical differentiators and real-world value data to justify premium pricing pre-biosimilar entry.
- Market Expansion: Secure approvals for additional indications to extend lifecycle and revenue streams.
- Regulatory Vigilance: Monitor patent landscapes and biosimilar developments to preempt market erosion.
- Reimbursement Engagement: Collaborate with payers early to establish value-based agreements and optimize market access.
Key Takeaways
- The market for NDC 59310-0406 functions within a high-growth, competitive environment, characterized by biologic innovation and biosimilar emergence.
- Current prices are in the $50,000–$150,000 range annually, with potential for moderation post-patent expiry.
- Projections suggest a gradual price decline of approximately 10-20% over five years, driven by biosimilar competition and value-based pricing.
- Strategic positioning hinges on demonstrating clinical advantages, expanding indications, and engaging proactively with payers.
- Monitoring regulatory and patent landscapes is crucial to mitigate risks and capitalize on market opportunities.
FAQs
Q1: What factors most influence the pricing of biologic drugs like NDC 59310-0406?
A1: Clinical efficacy, safety profile, manufacturing costs, patent status, market competition, and reimbursement policies predominantly influence biologic pricing.
Q2: How does biosimilar competition impact prices for biologics?
A2: Biosimilars typically enter the market at a 20-30% lower price, increasing competition and exerting downward pressure on the originator biologic’s price.
Q3: What is the typical patent life for biologic drugs, and how does it influence pricing?
A3: Biologics usually enjoy patent exclusivity for 12-20 years, allowing premium pricing during this period. Patent expiry opens the market to biosimilars, often reducing prices significantly.
Q4: How can companies prepare for biosimilar entry?
A4: By innovating with formulary advantages, expanding indications, demonstrating superior clinical outcomes, and engaging in value-based pricing negotiations.
Q5: What role do regulatory agencies play in shaping the market for biologics?
A5: Agencies like the FDA approve, regulate, and oversee patent protections, biosimilar pathways, and labeling, directly affecting market timelines and pricing strategies.
References
[1] IQVIA. "The Future of Biologics and Biosimilars." 2022.
[2] EvaluatePharma. "Global Market Trends in Biologics." 2023.
[3] CMS. "Value-Based Pricing Initiatives." 2022.
[4] Medicare Part B drug spending data. 2023.
Disclaimer: This analysis is based on publicly available data and inferential insights. For tailored commercial decisions, consult detailed market intelligence reports and conduct custom due diligence.
More… ↓
